Asset Details
Do you wish to reserve the book?
Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
Do you wish to request the book?
Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
2018
Overview
The poly(ADP‐ribose) polymerase‐1/2 inhibitor veliparib is active against tumors deficient in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended‐release (ER) were evaluated in patients with advanced solid tumors. This phase I study assessed veliparib‐ER up to 800 mg once daily or 600 mg twice daily. Dose‐limiting toxicities (DLTs), recommended phase II dose (RP2D), and maximum tolerated dose (MTD) were assessed in cycle 1 and safety/tolerability during continuous administration (28‐day cycles). Seventy‐one patients (n = 53 ovarian, n = 17 breast, n = 1 prostate carcinoma) received veliparib; 50 had deleterious breast cancer susceptibility (BRCA) gene mutations. Single‐dose veliparib‐ER 200 mg (fasting) led to 58% lower peak concentration and similar area under the concentration‐time curve compared with veliparib immediate‐release (IR). Three patients experienced DLTs (grade 2: asthenia; grade 3: nausea/vomiting, seizure). RP2D and MTD for veliparib‐ER were 400 mg BID. The most frequent adverse events (AEs) were nausea (78.9%) and vomiting (50.7%). The most common grade 3/4 treatment‐related AEs were as follows: thrombocytopenia (7.0%), nausea, and anemia (4.2% each). Overall, 12 (27.3%) patients with ovarian and 10 (62.5%) patients with breast carcinoma had a partial response. Veliparib‐ER, versus veliparib‐IR, exhibited an improved pharmacokinetic profile and was well tolerated in patients with ovarian and BRCA‐mutated breast cancers. Veliparib is active against tumors deficient in homologous DNA damage repair. This phase I study assessed the pharmacokinetics and safety of veliparib extended‐release (ER) versus veliparib immediate‐release (IR) in patients with advanced solid tumors. Veliparib‐ER, versus veliparib‐IR, exhibited an improved pharmacokinetic profile and was well tolerated in patients with ovarian and breast cancer susceptibility gene‐mutated breast cancers.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Asthenia
/ Benzimidazoles - pharmacokinetics
/ Benzimidazoles - therapeutic use
/ BRCA
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ extended‐release formulation
/ Female
/ Humans
/ Male
/ Nausea
/ Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
/ Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
/ Ribose
/ Safety
/ Tumors
/ Vomiting
